Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi's 5th Annual 3D Cell Culture

LONDON - Dec. 9, 2021 - PRLog -- Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi's 5th Annual 3D Cell Culture Conference 2022  on February 9th – 10th 2022, with two interactive pre-conference workshops on the February 8th, 2022.

The co-chairs bring over many years combined wealth of experience and knowledge to the conference, Philip Hewitt is currently the Merck assessment of more advanced cell models for safety testing and potential animal replacement. Stefan Pryzyborksi has 25 years' experience in cell biology and is currently developing new innovative approaches to manage the growth and function of cultured cells in ways that are more accurately reflective of native tissues.

Interested parties can register at http://www.3D-cellculture.com/PR2. Early bird offer and register by 17th December to save £100.

Co-chairs' invitation letter excerpt below:

'As the co-chairs of SMi's 5th Annual 3D Cell Culture Conference and on behalf of SMi Group, I am delighted to cordially invite you to our conference and workshops.
Experts and global authorities in the field will be joining us to look in depth at the production of complex, biologically relevant 3D cell models and their applications. Recent years have seen great leaps in the technological capabilities of the pharmaceutical industry, with 3D Cell Culture techniques at the forefront of some of the most critical clinically relevant applications of this time. From the use of Microphysiological Systems in research and development, drug safety assessment and biopharmaceutical discovery, to the advancements in the creation of organoids and complex bioengineered tissues that are quickly changing the face of drug screening and discovery.'

'This year's conference will also explore the regulatory perspective on this cutting-edge biotechnology. Furthermore, there will be in-depth assessment into the uses of 3D Bioprinting that are bringing in new ways of processing cells in media, as well as the generation of immune-competent microphysiological systems.'

Event Key Highlights Include:

• Discuss the uses of advanced cell technologies to construct in vitro models of human tissues
• Explore the regulatory sciences surrounding Microphysiological systems, and their development and adoption for drug safety assessment
• Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability
• Utilise 3D cell culture for High Throughput drug discovery and content screening over traditional 2D methods

Download brochure online at http://www.3D-cellculture.com/PR2

SMi's 5th Annual 3D Cell Culture 2022
Workshops: 8 February 2022
Conference: 9-10 February 2022
London, UK
http://www.3D-cellculture.com/PR2